Market Overview

What Investors Are Watching For In Regulus Therapeutics' Next Data Release

Benzinga's Top Upgrades, Downgrades For August 2, 2017
20 Biggest Mid-Day Losers For Thursday

Biotech companies that treat Hepatitis C were on fire in 2014. The leader of the pack, Gilead Sciences, Inc. (NASDAQ: GILD), had the most successful drug launch in history. AbbVie Inc (NYSE: ABBV) and Enanta Pharmaceuticals Inc (NASDAQ: ENTA) also got Viekira Pak approved in late 2014.

Additionally, Merck & Co., Inc. (NYSE: MRK) paid $3.5 billion to acquire Idenix Pharmaceuticals for its early stage Hepatitis C drug. Achillion Pharmaceuticals (NASDAQ: ACHN) is also up over 350 percent in the last year, due to enthusiasm over its nucleotide inhibitor for Hepatitis C.

Regulus Therapeutics Inc (NASDAQ: RGLS) participated in the trend too.

Regulus stock jumped over 100 percent when the company announced positive results from its lead microRNA drug called RG-101.

Unlike Gilead's pill, RG-101 is delivered with a single injection. In October, Regulus announced Phase 1 interim results that showed encouraging drops in viral loads. RG-101 was also safe and well tolerated.

Investors are now awaiting data from RG-101 in higher doses.

Related Link: Stocks That Battle Cancer Were The Best-Performing Biotechs In January

The company has guided that it expects to announce new updated results from RG-101 in early February.

The new results will include data from the viral load reduction in 4 mg/kg dosing cohort and a follow-up from the 2 mg/kg cohort.

It is expected that the full data will be released at the European Association for the Study of the Liver (EASL) conference in April.

In a recent report, analysts at Deutsche Bank stated: "The company has achieved proof of concept in targeting miRNAs in Hepatitis C patients and we view this as a major de-risking point for the platform. We believe Regulus has the opportunity to unlock significant long-term value for investors as this platform technology generates more clinical programs and matures."

The firm set a $30 price target for Regulus.

Latest Ratings for RGLS

Aug 2017BMO CapitalMaintainsMarket Perform
Aug 2017Chardan CapitalDowngradesBuyNeutral
Mar 2017WedbushReiteratesOutperform

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Previews FDA Analyst Ratings Trading Ideas


Related Articles (ACHN + ABBV)

View Comments and Join the Discussion!